Apollo's chief economist Torsten Slok challenges Wall Street's timeline for AI profitability outside technology companies. Slok argues that regulated industries, including healthcare, banking, and pharmaceuticals, will struggle to realize productivity gains from AI investments for years, not months.
The core constraint is regulatory compliance. Healthcare systems must navigate HIPAA requirements. Banks face strict data governance rules. Pharmaceutical companies operate under FDA oversight. These industries cannot deploy AI solutions quickly because they require extensive process redesigns, data cleanup, and regulatory approval before implementation.
Slok's analysis suggests companies in these sectors could wait five years or longer to see meaningful margin improvements from AI spending, compared to tech companies that realize gains in five months. This timeline mismatch creates a repricing risk for AI stocks that investors have valued on accelerated profitability assumptions.
Current market valuations assume broad-based AI adoption generates returns rapidly across all sectors. That assumption breaks down when regulated industries face compliance friction and legacy system constraints. A company spending millions on AI infrastructure while waiting years for regulatory clearance sees no near-term profit impact, undermining return-on-investment projections.
The timing issue matters because it extends capital deployment cycles. Spending on AI applications has increased substantially across industries, according to Ramp's analysis of billions in transactions. But deployment speed and profitability realization diverge sharply between tech and regulated sectors.
Slok's warning targets investor expectations, not AI capability. The technology works in regulated industries. The barrier is process change and compliance verification, not technical feasibility. Companies will eventually deploy AI effectively in healthcare, banking, and pharma. The delay simply means Wall Street's earnings acceleration thesis needs recalibration.
This creates a bifurcation where tech stocks capturing immediate AI margin gains stay resilient while non-tech AI beneficiaries face delayed returns and investor disappointment. For long-term AI investors